Movement Disorders

The safety profile in the low-dose cohort (6 x 1012 vg) is supportive of continued enrollment for a higher-dose cohort of 6 x 1013 vg. Additional data are anticipated to be announced in the second quarter of 2022.

Here's what is coming soon to NeurologyLive®.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 31, 2021.

Take a look back at some of the most-viewed, top video series with key experts in neurology and their in-depth discussions, part of NeurologyLive®'s Year in Review.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jennifer Majersik, MD, MS.

As part of NeurologyLive®'s Year in Review, take a look at some of the most engaging conversations the team has had with experts in neurology this past year.

As part of NeurologyLive®'s Year in Review, take a look at some of the most listened to and engaging conversations from the Mind Moments™ podcast from this past year.

These news stories were the top conversations in the field and were often included in NeurologyLive®'s coverage in movement disorders such as Parkinson disease, Huntington disease, and essential tremor, among others.

As part of NeurologyLive®'s Year in Review, take a look at some of the biggest FDA approvals and decisions from this past year.

As part of NeurologyLive®'s Year in Review, take a look at some of the best features that have been published on the site this year.

Here's what is coming soon to NeurologyLive®.

Take a look back at some of the most top video interviews with key experts in neurology and their insights and perspectives on topics in neurology subspecialties, as part of NeurologyLive®'s Year in Review.

Although combination carbidopa-levodopa has become a standard for the treatment of many of the motor features of PD to this day, gait dysfunction remains a difficult symptom to treat.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 24, 2021.

The diagnosis of Parkinson disease may seem straightforward at first, requiring neurologists to rely on their eyes and hands, but the treatment process can present challenges for both physicians and patients.

Here's what is coming soon to NeurologyLive®.

The newly awarded programs complement AC Immune’s portfolio in PD, which includes an anti-α-syn vaccine, next generation PET imaging tracer, and a preclinical stage anti-α-syn antibody.

Neurology News Network for the week ending December 18, 2021. [WATCH TIME: 3 minutes]

Pharma Two B anticipates filing a new drug application to the FDA for the investigational treatment in 2022.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 17, 2021.

Over a 10-year period, apomorphine sublingual film was projected to be dominant in 70% of patients compared with apomorphine hydrochloride injection and 71% vs levodopa inhalation powder.

Here's what is coming soon to NeurologyLive®.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 10, 2021.

Here's what is coming soon to NeurologyLive®.

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive® team.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 3, 2021.

The approval expands the devices existing indications for medication-refractory essential tremor and tremor-dominant Parkinson disease.

Expert clinicians offer their perspectives on transitional care in pediatric MS, a biomarker for SUDEP, and a novel approach to narcolepsy, among other topics.

As more organizations begin to adopt palliative care practices for patients with Parkinson disease, some may turn to the implemented plans of Cleveland Clinic as an example to follow.

Here's what is coming soon to NeurologyLive®.